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humanized mice were generated by injecting immunodeficient non-obese diabetic severe combined immunodeficiency interleukin-2 receptor γ common chain null (NSG) mice with human peripheral blood mononuclear cells (hPBMCs). Clinical GVHD development was assessed using established scoring criteria (weight loss, posture, activity, fur texture and skin integrity). Differences between humanized NSG mice that developed clinical or subclinical GVHD were then compared. Both groups of mice demonstrated similar frequencies of human leukocyte engraftment. In contrast, mice that developed clinical GVHD demonstrated increased histological damage compared to mice with subclinical GVHD. Furthermore, mice with clinical GVHD exhibited increases in the splenic human CD4 + :CD8 + T cell ratio, serum human interferon (IFN)-γ and intestinal human interleukin (IL)-17 expression compared to mice with subclinical GVHD. These cellular and molecular changes could be used as potential markers of disease progression in this preclinical model. This study also provides further insights into GVHD development which may be relevant to human HSCT recipients.
HIGHLIGHTS:
• GVHD development in humanized mice is variable with the majority developing clinical disease but a small proportion with subclinical disease.
• Mice with clinical GVHD demonstrate increased splenic human CD4 + :CD8 + T cell ratios compared to mice with subclinical GVHD. Treg, regulatory T cell.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative therapy for haematological malignancies and other blood disorders. However, graft-versus-host disease (GVHD) occurs in approximately half of the HSCTs conducted annually [1] and leads to a mortality rate of approximately 20% in these patients [2] . GVHD emerges when effector donor T cells mount an immune response against host tissues [3] . GVHD is characterized by three stages. The first stage is release of danger signals from cells damaged by the underlying disease and/or conditioning regimes, followed by CD4 + T cell activation by antigen presenting cells resulting in cytokine release, and finally CD4 + and CD8 + T cell-mediated inflammatory damage [4, 5] . This damage can be propagated by the "cytokine storm" in the latter stage, wherein Th1 and Th17 cells release pro-inflammatory cytokines such as interferon (IFN)-γ [4, 5] and interleukin (IL)-17 [6, 7] , respectively, perpetuating a feed forward loop of inflammation. Conversely, regulatory T (Treg) cells can modulate effector T cells to reduce T cell-mediated inflammatory damage in GVHD [8] . Current therapies for GVHD are limited, with the standard therapy being general immunosuppression achieved through steroids, leaving patients susceptible to subsequent infections and/or disease relapse [9] . Therefore, greater understanding of the mechanisms important in GVHD and elucidation of new therapies is essential to improve outcomes in HSCT patients and prevent GVHD.
Current studies into potential therapeutics for GVHD are investigated in allogeneic mouse models before translation to the clinic. However, potentially due to large species differences between humans and mice, therapies that delay or prevent GVHD in allogeneic mouse models often do not translate to the clinic. To address this, previous studies have developed a range of preclinical "humanized" mouse models [10] . The most commonly used of these models is the humanized immunodeficient non-obese diabetic severe combined immunodeficiency interleukin-2 receptor γ common chain null (NSG) mouse, developed by Shultz et al. [11] wherein mice readily engraft human peripheral blood mononuclear cells (hPBMCs) due to three defects. First, the Scid mutation prevents V(D)J recombination to impair B and T cell development [12] . Second, deletion of the Il2rg gene results in absence of natural killer (NK) cells. Third, a polymorphism in the Sirpa gene, present due to backcrossing onto a NOD background, promotes phagocytic tolerance of xenogeneic leukocytes [13] . Human T cells recognize major histocompatibility complex (MHC) class I and II of NSG mice to cause GVHD in this humanized mouse model [14] , demonstrating that human T cell responses can be investigated in vivo to better understand this disease in a preclinical setting. The humanized NSG model of GVHD is emerging as a valuable intermediate to allow translation of findings identified in allogeneic mouse models to human clinical trials. For example, based on an earlier study in an allogeneic mouse model of GVHD [15] , King, et al. [14] demonstrated tumour necrosis factor (TNF)-α blockade could reduce GVHD severity in this humanized mouse model, and etanercept, an anti-TNF-α monoclonal antibody (mAb) has subsequently shown efficacy in clinical trials [16] . More recently, Burger et al. [17] demonstrated an anti-CCR5 mAb (PRO 140) could reduce GVHD in humanized NSG mice, with this mAb now being investigated in clinical trials [18] . Finally, the discovery of Treg cells, and their therapeutic potential in GVHD has progressed from allogeneic mouse models [8] , to humanized NSG models [19, 20] , and finally to clinical trials [21] . Moreover, this model has helped elucidate the action of post-transplant cyclophosphamide on Treg cells in GVHD development [22] . Therefore, the humanized NSG model offers a valid preclinical model to test therapies for translation to the clinic. Although this mouse model has offered numerous advancements, the characterization of GVHD in these mice has not been adequately described.
OBJECTIVE
The current study aimed to investigate the characteristics of GVHD that were observed in humanized NSG mice injected with human PBMCs that developed clinical disease compared to those mice that displayed subclinical GVHD. This study demonstrated that all humanized NSG mice had similar engraftment of human leukocytes, which were predominantly T cells.
In contrast, humanized NSG mice with clinical GVHD demonstrated greater splenic CD4 + :CD8 + T cells ratios, serum human IFN-γ concentrations and intestinal human IL-17 expression than humanized mice with subclinical GVHD. These cellular and molecular changes could potentially be used as biomarkers of disease progression in this preclinical model and provide insights into GVHD development which may be applicable to human HSCT recipients.
MATERIALS AND METHODS

Antibodies for flow cytometry
Fluorescein isothiocyanate (FITC)-conjugated mouse anti-hCD4 (clone: RPA-T4), and mouse anti-hCD45 (clone: HI30); R-phycoerythrin (PE)-conjugated mouse anti-hCD3 (clone: UCHT1) and mouse anti-hCD8 (clone: RPA-T8); peridinin chlorophyll protein (PerCP)-Cy5.5 conjugated mouse anti-hCD4 (clone: L200) and rat anti-mCD45 (clone: 30-F11); and allophycocyanin (APC)-conjugated mouse anti-hCD3 (clone: UCHT1) and mouse anti-hCD19 (clone: HIB19) mAb were obtained from BD (San Jose, CA, USA).
Mice
All mouse experiments were conducted in accordance with approval by the Animal Ethics Committee, University of Wollongong (Wollongong, Australia). Female NSG mice, originally obtained from The Jackson Laboratory (Bar Harbor, ME, USA), were bred at the Westmead Animal Research Facility (Westmead, Australia) or Australian BioResources (Moss Vale, Australia). NSG mice, obtained at 6-10 weeks of age, were housed in filter top cages in Tecniplast (Buggugiate, Italy) isolation cabinets, and provided with autoclaved food and water, ad libitum. Mice were allowed to acclimatize for one week prior to injection.
Isolation of human PBMCs
All experiments with human blood were conducted in accordance with approval by the Human Ethics Committee, University of Wollongong. Peripheral blood was collected by venepuncture into VACUETTE® lithium heparin tubes (Greiner Bio-One; Frickenhausen, Germany). Whole blood, diluted with an equal volume of sterile phosphate buffered saline (PBS) (Thermo Fisher Scientific, Waltham, USA), was underlaid with Ficoll-Paque PLUS (GE Healthcare; Uppsala, Sweden) and centrifuged (560 x g for 30 min). hPBMCs were collected and washed with PBS (430 x g for 5 min) and resuspended in PBS.
Humanized NSG mouse model of GVHD
NSG mice were injected intra-peritoneally (i.p) with 10 x 10 6 hPBMCs (from the same donor) in 100 μL sterile PBS (hPBMC group) or with 100 μL sterile PBS alone (control group) (day 0). Mice were checked for engraftment of hPBMCs at 3 weeks post-injection by immunophenotyping tail blood. Mice were monitored up to week 8 for signs of GVHD using a scoring system [23] giving a total clinical score out of 10 (Table 1) . Mice were euthanized at end-point either 8 weeks post-injection or earlier if exhibiting a clinical score of ≥ 8 or a weight loss of ≥ 10%, according to the approved animal ethics protocol.
Immunophenotyping by flow cytometry
Tail blood (20-30 μL) was collected 3 weeks post-hPBMC injection into 200 μL of citrate solution (Sigma-Aldrich), diluted with PBS and centrifuged (500 x g for 5 min). Spleens from euthanized mice at end-point were mechanically dissociated, filtered through 70 μm nylon filters (Falcon Biosciences, New York, NY, USA) and centrifuged (300 x g for 5 min). Blood and spleen cells were incubated with ammonium chloride potassium (ACK) lysis buffer (150 mM NH 4 Cl, 1 mM KHCO 3 , 0.1 mM Na 2 CO 3, pH 7.3) for 5 min and washed in PBS (300 x g for 5 min). Cells were then washed in PBS containing 2% foetal bovine serum (300 x g for 3 min), and incubated for 30 min with fluorochrome-conjugated mAb, including respective isotype controls. Cells were washed with PBS (300 x g for 3 min) and data was collected using a BD LSRII Flow Cytometer (using band pass filters 515/20 for FITC, 575/26 for PE, 675/40 for PerCP-Cy5.5, and 660/20 for APC). The relative percentages of cells were analyzed using FlowJo software v8.7.1 (TreeStar Inc., Ashland, OR, USA).
Histological analysis
Tissues from euthanized mice at end-point were incubated overnight in neutral buffered (10%) formalin (Sigma-Aldrich). Fixed tissues were removed, coated in paraffin, sectioned (5 μm) and stained with haematoxylin and eosin (POCD; Artarmon, Australia). Histological changes were assessed using a Leica (Wetzlar, Germany) DMRB microscope and Leica Application Software version 4.3.
RNA isolation and cDNA synthesis
Tissues from euthanized mice at end-point or freshly isolated hPBMCs were stored in RNAlater (Sigma-Aldrich) at -20°C. RNA was isolated using TRIzol reagent (Thermo Fisher Fig 1A) . By end-point it became apparent that hPBMC-injected mice segregated into one of two groups based on clinical score (Table 1) ;
one group with scores ≥ 3 (clinical GVHD) and another group with scores < 3 (subclinical GVHD) ( Fig 1A) . Mice with clinical scores ≥ 3 exhibited weight loss, reduced activity, postural changes (hunching) and fur ruffling, with skin involvement in some mice, whilst mice with clinical scores < 3 was solely attributed to fur ruffling and/or postural changes (data not shown). The mean clinical score over the course of the experiment in humanized mice with clinical GVHD was greater than both control mice and mice with subclinical GVHD (P < 0.0001 and P = 0.0010, respectively) ( Fig 1A) . Weight loss alone is indicative of GVHD development [24] . Notably, control mice and humanized mice with subclinical GVHD continued to gain weight over the entire 8 weeks, however, humanized mice with clinical GVHD started to lose weight after 4 weeks ( Fig 1B) . Although this difference was obvious after 4 weeks, the weight loss was not statistically significant between groups (P = 0.2871). Humanized mice with clinical GVHD had a MST of 50 days, which was significantly worse than control mice (P < 0.0001) and humanized mice with subclinical GVHD (P < 0.0001) where all mice survived for 8 weeks (Fig 1C) . Humanized mice with clinical GVHD exhibited an 80% mortality rate over 8 weeks, which was significantly greater than control mice (P < 0.0001) or humanized mice with subclinical GVHD (P = 0.0350) ( Fig   1C) .
Increased histological damage and leukocyte infiltration is associated with clinical GVHD
GVHD targets the liver, gastro-intestinal tract and skin in humanized NSG mice [14, 23] , similar to humans [5] . 
Similar engraftment of hPBMCs in mice with subclinical and clinical GVHD
To confirm that NSG mice injected with hPBMCs engrafted human leukocytes, blood was collected at 3 weeks post-injection and spleens were collected at end-point and analyzed by flow cytometry. Blood (Fig 3A-D) and spleens ( Fig 3E-J) revealed both murine (m) and human (h) CD45 + cells in hPBMC-injected mice (Fig 3A, E) . As expected, control mice demonstrated mCD45 + but no hCD45 + cells in the blood and spleen (Fig 1B, F) .
The frequency of hCD45 + leukocytes were calculated as a percentage of total hCD45 + and mCD45 + cells. In the blood, mean hCD45 + engraftment was similar between mice with subclinical GVHD (15.1 ± 2.2 %, n = 3) and mice with clinical GVHD (15.3 ± 3.2, n = 10) (P = 0.9737) ( Fig 3B) . hCD45 + cells in the blood of hPBMC-injected mice were then analyzed for the presence of hCD3 + (human T cells) and hCD19 + cells (human B cells) ( Fig 3A) . NSG mice injected with hPBMCs showed the majority of engrafted human leukocytes were T cells. The mean percentage of T cells in blood did not differ between mice with subclinical GVHD (99.1 ± 0.1%, n = 3) or clinical GVHD (98.1 ± 0.4%, n = 10) (P = 0.1500) ( Fig 3C) .
The remaining cells in the blood were hCD3and hCD19 -, the frequencies of which did not differ between mice with subclinical GVHD (0.8 ± 0.1%, n = 3) or clinical GVHD (1.8 ± 0.4%, n = 10) (P = 0.1869) ( Fig 3D) .
Similar to blood, mean hCD45 + engraftment in spleens at end-point was similar between mice with subclinical GVHD (90.9 ± 1.7%, n = 3) and clinical GVHD (87.7 ± 2.9%, n = 10, respectively) (P = 0.5880) ( Fig. 3F) . Moreover, NSG mice injected with hPBMCs showed the majority of engrafted human leukocytes in spleens were T cells. The mean percentage of T cells in spleens did not differ between mice with subclinical GVHD (97.8 ± 0.5%, n = 3) or clinical GVHD (98.4 ± 0.2%, n = 10) (P = 0.1942) ( Fig 3G) . The remaining cells in spleens were hCD3and hCD19 -, the frequencies of which did not differ between mice with subclinical GVHD (2.2 ± 0.5%, n = 3) or clinical GVHD (1.6 ± 0.2%, n = 10) (P = 0.1942) ( Fig 3H) .
Further analysis of the splenic human T cells (hCD3 + hCD19cells) ( Fig 3E) revealed that mice with clinical GVHD demonstrated significantly greater proportions of hCD4 + T cell engraftment (85.1 ± 2.0%, n = 10) than mice with subclinical GVHD (45.5 ± 8.4%, n = 3) (P < 0.0001) ( Fig 3I) . Conversely, mice with clinical GVHD demonstrated significantly lower proportions of hCD8 + T cell engraftment (12.8 ± 1.7%, n = 10) than mice with subclinical GVHD (50.9 ± 8.8%, n = 3) (P < 0.0001) ( Fig 3I) . Moreover, mice with clinical but not subclinical GVHD demonstrated a significantly greater proportion of hCD4 + than hCD8 + T cells (P < 0.0001), resulting in higher splenic hCD4 + :hCD8 + T cell ratios (8.5 ± 1.7, n = 10)
than mice with subclinical GVHD (1.0 ± 0.3, n = 3) (P = 0.0418) ( Fig 3J) .
Increased serum human IFN-γ is associated with clinical GVHD
IFN-γ has been implicated in GVHD pathogenesis [25] and correlates to worse disease in mice with allogeneic GVHD [26] . Therefore, to determine if humanized NSG mice with GVHD demonstrate changes in hIFN-γ, mRNA expression and serum concentrations of this cytokine were analyzed by qPCR and ELISA at end-point, respectively. There was a 3-fold increase in relative hIFN-γ expression in spleens from mice with clinical GVHD (0.7 ± 0.2, n = 3) compared to mice with subclinical GVHD (0.2 ± 0.1, n = 3) (P = 0.0880) ( Fig 4A) .
There was also a 1.5-fold increase in relative hIFN-γ expression in livers from mice with clinical GVHD (0.9 ± 0.1, n = 3) compared to mice with subclinical GVHD (0.6 ± 0.3, n = 3) (P = 0.2576) ( Fig 4B) . However, small intestines from humanized mice with subclinical GVHD or clinical GVHD demonstrated similar relative hIFN-γ expression (0.7 ± 0.3 vs 0.9 ± 0.1, n = 3) (P = 0.5907) ( Fig 4C) . Notably, mice with clinical GVHD demonstrated significantly increased serum human IFN-γ concentrations (42.9 ± 2.7 ng/mL, n = 10) compared to mice with subclinical GVHD (25.0 ± 5.5 ng/mL, n = 3) (P = 0.0155) ( Fig 4D) .
Increased intestinal hIL-17 is associated with clinical GVHD
IL-17 exacerbates GVHD in allogeneic mouse models of this disease [27, 28] and in HSCT patients [29] . Whilst, FoxP3 Treg cells exert anti-inflammatory effects in allogeneic [8] and humanized mouse models [30] , as well as in humans [31] to prevent GVHD. To further explore potential immunological differences between humanized NSG mice with subclinical or clinical GVHD, relative mRNA expression of hIL-17 and hFoxP3 in the spleen, liver and small intestine was assessed by qPCR at end-point.
Relative splenic hIL-17 expression in mice with clinical GVHD (0.5 ± 0.2, n = 3) was 40% lower compared to mice with subclinical GVHD (1.3 ± 0.5, n = 3) (P = 0.2505) ( Fig 5A) .
However, hepatic hIL-17 expression was similar between mice with clinical GVHD (1.5 ± 0.9, n = 3) and subclinical GVHD (1.2 ± 0.2, n = 3) (P = 0.7717) ( Fig 5B) . Notably, intestinal hIL-17 expression was evident in mice with clinical GVHD (1.8 ± 0.4, n = 3) but was absent in mice with subclinical GVHD (0.0 ± 0.0, n = 3) ( Fig 5C) .
Relative splenic hFoxP3 expression was similar in humanized mice with subclinical GVHD (1.2 ± 1, n = 3) or clinical GVHD (0.6 ± 0.2, n = 3) (P = 0.5669) ( Fig 5D) . Relative hepatic hFoxP3 expression was also similar in humanized mice with subclinical GVHD (1.3 ± 0.5, n = 3) or clinical GVHD (0.6 ± 0.2 and 2.0 ± 0.8, n = 3) (P = 0.4838) ( Fig 5E) . However, there was a 17-fold but variable increase in intestinal hFoxP3 expression in mice with clinical GVHD (0.5 ± 0.3, n = 3) compared to mice with subclinical GVHD (0.03 ± 0.01, n = 3) (P = 0.2020) ( Fig 5F) .
DISCUSSION
Humanized NSG mouse models of GVHD are used as preclinical models to test potential therapeutics [10] , however these models have not been fully characterized. The current study compared humanized NSG mice with subclinical and clinical GVHD, which paralleled the degree of histological disease. Notably, mice with clinical GVHD exhibited greater splenic hCD4 + :hCD8 + T cell ratios, serum hIFN-γ concentrations and intestinal hIL-17 expression than mice with subclinical GVHD. However, it should be noted that in two other independent experiments with hPBMCs from two different donors all NSG mice developed clinical GVHD (data not shown).
Humanized mice with a clinical score < 3 were defined as having subclinical GVHD, and only showed signs of mild to moderate fur ruffling and/or hunching only at rest. These two criteria compared to the other three criteria used are relatively subjective [32] , and thus may be attributed to events such as being recently awoken rather than GVHD per se. Analysis of liver, small intestine and skin revealed that all humanized NSG mice had histological evidence of GVHD (leukocyte infiltration, apoptosis and/or tissue damage). Although the leukocyte infiltrates in these tissues were not assessed, previous studies have confirmed infiltrates comprise hCD45 + leukocytes [14] predominantly hCD3 + T cells [33, 34] , comprising hCD4 + and hCD8 + T cells [35] . Of note, histological evidence of GVHD was more apparent in humanized mice with clinical GVHD compared to those with subclinical GVHD. The reduced histological GVHD in mice with subclinical GVHD is similar to that observed in the livers [33, 34, 36, 37] and small intestine [33, 38] of humanized mice following various treatments to prevent GVHD. To this end, the current study provided the opportunity to examine differences in humanized mice with subclinical versus clinical GVHD, and to determine factors that correspond with clinical GVHD development. However, the lung and bone marrow are also affected in the humanized NSG mouse model of GVHD [14, 35] . Thus, future studies could also compare these tissues in humanized NSG with subclinical and clinical GVHD.
Both humanized NSG mice with subclinical or clinical GVHD were engrafted with similar proportions of human leukocytes as shown indirectly by histology of spleens and directly by flow cytometry of peripheral blood (week 3) and spleens (at end-point). However, the splenic hCD4 + :hCD8 + T cell ratios were significantly greater in humanized mice with clinical GVHD compared to mice with subclinical GVHD. This finding is consistent with observations that disease development in humanized NSG mice is mediated by hCD4 + T cells [14, 39] .
Furthermore, the high CD4 + :CD8 + T cell ratios in humanized mice with clinical GVHD parallels with studies in humans, in which high CD4 + :CD8 + T cell ratios indicate greater disease severity [40, 41] . These observations contrast other findings in humanized NSG mice, where increased hCD4 + :hCD8 + T cell ratios correlated with reduced disease severity following IL-21 blockade to prevent GVHD [42] . However, this treatment reduced the Serum hIFN-γ concentrations were significantly increased in humanized NSG mice with clinical GVHD compared to those with subclinical GVHD. There was also a trend of increased hIFN-γ expression in the spleens and livers of mice with clinical GVHD. Reduced serum IFN-γ has been used as a marker to demonstrate a reduction in disease severity in allogeneic [44] and humanized mouse models [23, 45] following treatments to prevent GVHD. However, the current study is the first to demonstrate that increased serum hIFN-γ concentrations in humanized mice are associated with clinical GVHD. A recent study by Ehx, et al. [46] confirms our previous findings [23] , that CD8 + T cells are the prominent producers of hIFN-γ in NSG mice, but CD4 + T cells have also been shown to produce hIFN-γ [35] .
Therefore, it would be of value to determine if blockade or knockdown of hIFN-γ prevents Thus, the increased IL-17 expression in the small intestines of mice with clinical GVHD may reflect increased pathology or a compensatory mechanism to protect against intestinal GVHD in these mice.
In conclusion, the current study identified increases in splenic hCD4+:hCD8+ T cell ratios, Mice are assigned a score out of 2 for each of the criterion outlined to give a total score of 10 (as previously described [23] ). Humanized mice with clinical score < 3 were defined as subclinical GVHD, and mice with a clinical score ≥ 3 were defined as clinical GVHD. 
